TELIMMUNE PLASMA SEPARATION CARDS
(Formerly Noviplex)
Plasma is the preferred specimen for most in-vitro analytical methods used to identify and quantify biomarkers.
Traditional analysis has been done through a fractionation process requiring venipuncture, cold chain transport, biohazard mitigation, and centrifugation – an expensive, invasive, and time-consuming endeavor.
Our cards were founded under the premise that there must be a better way.
After a simple fingerstick, a drop or two of blood is applied to the card, then plasma is automatically fractionated from a whole blood specimen, delivering ≈ 3uL of plasma (per disc) in 3 minutes. The collection disc may be air-dried to stabilize the sample which may then be inexpensively and safely transported for in-vitro analysis.
Simultaneous Cell Partition Technology (SCPT) eliminates metabolic effects associated with standard liquid phlebotomy samples.
​
Common applications include remote blood collection, metabolomics studies, protein biomarkers, drug testing, and more.
INSTRUCTIONAL VIDEOS
TECHNICAL SPECIFICATIONS
PHYSICAL PROPERTIES
​
-
FDA class 1 medical device
-
Compatible with standard 96 well formats
-
Cards do not show hematocrit effects
-
Suitable in temperature ranges from -5°F to 110°F
-
Volumetric precision: < 5% variation
HIGH SENSITIVITY ANALYTICAL TECHNIQUES
​
-
LC/MS
-
ELISA
-
PCR
-
QPCR
-
Enzymatic
COMPETITIVE ADVANTAGES
STUDIES, LITERATURE, INSTRUCTIONS
TESTIMONIAL
“Duchenne Muscular Dystrophy (DMD) boys’ veins are challenging to phlebotomize. Given the painful hardship multiple blood draws pose, we collaborated with a team of experts to rapidly develop and validate a novel method using the Telimmune Duo Plasma Separation Cards which requires only two drops of whole blood from a finger stick!
This innovative technology provides exceptional precision and stability for measuring our drug product's pharmacokinetic (PK) profile and its metabolite, thereby circumventing the pain and inconvenience of multiple venipunctures for DMD boys. We couldn’t be more thrilled by the results of our validation and stability analyses using the Telimmune Plasma Separation Cards and look forward to generating the PK profiles of our drug product using them in our ongoing DMD clinical trial.”
Ines Macias-Perez, Ph.D
Principle Scientist, Product Development
Cumberland Pharmaceuticals
APPLICATIONS
Known uses for our plasma separation cards include but are not limited to:
• Global and local clinical trials
• Therapeutic drug monitoring
• Accessibility in the developing world
• Neonatal screening
• Population-based research
• Toxicokinetic/pharmacokinetic studies
• Epidemiology
• Biomarker analysis
• Animal research
• SARS-CoV-2 antibodies (ELISA)
TELIMMUNE™ PLASMA SEPARATION CARD QUALITY
Telimmune Plasma Separation cards undergo extensive testing to ensure quality.
Telimmune cards are packaged in a hermetically sealed barrier pouch to protect the device from possible environmental factors. Each lot of cards undergoes quality assurance testing to ensure consistent performance prior to being released to market. An internal standard is used to correct for sample volume variations.
PLASMA VOLUME PRECISION
Telimmune plasma collection discs are weighed to ensure that a consistent amount of plasma is collected. Plasma volume is tested to ensure that each production lot of cards can provide a similar amount of plasma. Plasma volume precision is typically less than 5% for the standard Telimmune card.
HEMOLYSIS
The major challenge in preparing plasma by filtration is to prevent hemolysis. Forcing blood through a membrane often causes severe hemolysis. The resulting plasma is pink if not red in color due to contamination by hemoglobin. This level of contamination can interfere with subsequent analyses. The Telimmune card uses capillary action to slowly pull the blood through the membrane, resulting in less than 1% hemolysis.
